In TCGA PAAD datasets, 70% pancreatic cancer patients with KRAS mutations were un-responsive to cancer therapy, while, 49% patients without KRAS mutations were un-responsive to cancer therapy (Figure 7C). The gene discussed is KRAS; the disease is familial pancreatic carcinoma.